Page 44 - 南京医科大学学报自然科学版
P. 44
第41卷第11期
·1606 · 南 京 医 科 大 学 学 报 2021年11月
[5] DALY M B,PILARSKIR,BERRY M,et al. NCCN guide⁃ [18] 中国医师协会精准治疗委员会乳腺癌专业委员会,中
lines insights:genetic/familial high ⁃ risk assessment: 华医学会肿瘤学分会乳腺肿瘤学组,中国抗癌协会乳
breast and ovarian,version 2.2017[J]. J Natl Compr 腺癌专业委员会,等. 中国乳腺癌患者BRCA1/2基因检
Canc Netw,2017,15(1):9-20 测与临床应用专家共识(2018 年版)[J]. 中国癌症杂
[6] KNIJNENBURG T A,WANG L,ZIMMERMANN M T,et 志,2018,28(10):787-800
al. Genomic and molecular landscape of DNA damage re⁃ [19] ARPINO G,PENSABENE M,CONDELLO C,et al. Tu⁃
pair deficiency across the cancer genome atlas[J]. Cell mor characteristics and prognosis in familial breast cancer
Rep,2018,23(1):239-254 [J]. BMC Cancer,2016,16(1):924
[7] VAN’T VEER L J,DAI H,VAN DE VIJVER M J,et al. [20] WANG Y A,JIAN J W,HUNG C F,et al. Germline breast
Gene expression profiling predicts clinical outcome of cancer susceptibility gene mutations and breast cancer
breast cancer[J]. Nature,2002,415(6871):530-536 outcomes[J]. BMC Cancer,2018,18(1):315
[8] LIU Y,YANG B,ZHANG X,et al. The gene mutation [21] KUCHENBAECKER K B,HOPPER J L,BARNES D R,
spectrum of breast cancer analyzed by semiconductor se⁃ et al. Risks of breast,ovarian,and contralateral breast
quencing platform[J]. Pathol Oncol Res,2020,26(1): cancer for BRCA1 and BRCA2 mutation carriers[J].
491-497 JAMA,2017,317(23):2402-2416
[9] PILIE P G,GAY C M,BYERS L A,et al. PARP inhibi⁃ [22] WANG J,LI W,SHI Y,et al. Germline mutation land⁃
tors:extending benefit beyond BRCA⁃mutant cancers[J]. scape of Chinese patients with familial breast/ovarian can⁃
Clin Cancer Res,2019,25(13):3759-3771 cer in a panel of 22 susceptibility genes[J]. Cancer Med,
[10] ZHAO E Y,SHEN Y,PLEASANCE E,et al. Homologous 2019,8(5):2074-2084
recombination deficiency and platinum⁃based therapy out⁃ [23] MAHDAVI M,NASSIRI M,KOOSHYAR M M,et al. He⁃
comes in advanced breast cancer[J]. Clin Cancer Res, reditary breast cancer;Genetic penetrance and current
2017,23(24):7521-7530 status with BRCA[J]. J Cell Physiol,2019,234(5):
[11] HOPPE M M,SUNDAR R,TAN D S,et al. Biomarkers 5741-5750
for homologous recombination deficiency in cancer[J]. J [24] PODRALSKA M,ZIOLKOWSKA ⁃ SUCHANEK I,
Natl Cancer Inst,2018,110(7):704-713 ZURAWEK M,et al. Genetic variants in ATM,H2AFX
[12] RICHARDS S,AZIZ N,BALE S,et al. Standards and and MRE11 genes and susceptibility to breast cancer in
guidelines for the interpretation of sequence variants:a the polish population[J]. BMC Cancer,2018,18(1):
joint consensus recommendation of the American College 452
of Medical Genetics and Genomics and the Association [25] LANG G T,SHI J X,HU X,et al. The spectrum of BRCA
for Molecular Pathology[J]. Genet Med,2015,17(5): mutations and characteristics of BRCA⁃associated breast
405-424 cancers in China:Screening of 2 991 patients and 1 043
[13]刘继永,沈洪兵,靳光付,等. 江苏地区乳腺癌危险因素 controls by next⁃generation sequencing[J]. Int J Cancer.
的病例对照研究[J]. 南京医科大学学报(自然科学 2017,141(1):129-142
版),2008,28(5):689-692 [26] BERNSTEIN J L,GROUP W,CONCANNON P. ATM,ra⁃
[14] ZHAO W,HU H,MO Q,et al. Function and mechanism diation,and the risk of second primary breast cancer[J].
of combined PARP⁃1 and BRCA genes in regulating the Int J Radiat Biol,2017,93(10):1121-1127
radiosensitivity of breast cancer cells[J]. Int J Clin Exp [27] LI J,MEEKS H,FENG B J,et al. Targeted massively para⁃
Pathol,2019,12(10):3915-3920 llel sequencing of a panel of putative breast cancer sus⁃
[15] ROBERT M,PATSOURIS A,FRENEL J S,et al. Emerg⁃ ceptibility genes in a large cohort of multiple⁃case breast
ing PARP inhibitors for treating breast cancer[J]. Expert and ovarian cancer families[J]. J Med Genet,2016,53
Opin Emerg Drugs,2018,23(3):211-221 (1):34-42
[16] O’KANE G M,CONNOR A A,GALLINGER S. Charac⁃ [28] VAN O N,ROELEVELD N,WEEMAES C M,et al.
terization,detection,and treatment approaches for homolo⁃ Health risks for ataxia ⁃ telangiectasia mutated heterozy⁃
gous recombination deficiency in cancer[J]. Trends Mol gotes:a systematic review,meta⁃analysis and evidence⁃
Med,2017,23(12):1121-1137 based guideline[J]. Clin Genet,2016,90(2):105-117
[17]REBBECK T R,MITRA N,WAN F,et al. Association of [29] STAGNI V,MANNI I,OROPALLO V,et al. ATM kinase
type and location of BRCA1 and BRCA2 mutations with sustains HER2 tumorigenicity in breast cancer[J]. Nat
risk of breast and ovarian cancer[J]. JAMA,2015,313 Commun,2015,6:6886
(13):1347-1361 [收稿日期] 2021-02-03